Results · Apr-Jun 2026 · filed 14 Aug 2026
Dishman Carbogen Amcis Q1 FY27 results
Sales fell 4% to ₹678 crore from ₹708 crore in Apr-Jun 2025.
Operating profit fell 57% to ₹60.1 crore, an operating margin of 8.9% (down 11.0 points from a year ago).
Net profit turned into a loss of ₹57.9 crore, from a profit of ₹23.4 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −20%, swings to a loss.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 677.6 | 708.1 | −4% |
| Operating profit (EBITDA) | 60.1 | 140.7 | −57% |
| Operating margin | 8.9% | 19.9% | −11.0 pts |
| Net profit | -57.9 | 23.4 | swings to a loss |
Consolidated figures. Margins & ratios change in percentage points (pts).
The earnings call
Apr–Jun 2026 revenue fell 4% to ₹678 crore due to a deferred order worth ₹1 crore; EBITDA fell to ₹60 crore from ₹141 crore. Management expects single-digit FY27 growth & EBITDA margins similar to last year, with double-digit growth targeted for FY28-29 from India operations & Swiss/French entities.
The last 7 quarters
Filings that week
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Allotment
- 17 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 14 Aug 2026Board Meeting Outcome for UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS'' LIMITED REVIEW REPORT FOR THE FIRST QUARTER ENDED30/06/2026
- 14 Aug 2026UN-AUDITED FINANCIAL RESULTS AND STATUTORY AUDITORS''LIMITED REVIEW REPORT FOR THE FIRST QUARTER ENDED30/06/2026
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- 12 Aug 2026Board Meeting Outcome for Board Meeting Outcome For BOARD APPROVES ISSUE OF SENIOR, SECURED, RATED, LISTED, TRANSFERABLE, REDEEMABLE, TAXABLE NON-CONVERTIBLE DE
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.